Search

Lymphomas from A to Z

Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.

Read more

Report Drug Shortages to EHA

In an effort to mitigate shortages of hematologic drugs in Europe, EHA is collecting and compiling reports of shortages. Are you experiencing, or foreseeing drug shortages in your clinical practice?

Please report those to drugshortage@ehaweb. org.

Read more

How to apply for TRTH

Download the letter of intent template.  Fill in the template and get it duly signed. When you are ready, access the EHA Portal at http://eha. fluxx. io. and register yourself by clicking on the ‘Create an Account’ button.

Read more

How to apply for CBTH

TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.

Read more

Granulocytes & Constitutional Marrow Failures Disorders

The Specialized Working Group (SWG) on Granulocytes and Constitutional Marrow Failure Syndromes (G&CMFS) derives from the fusion of the formerly existing SWG on Granulocyte and Monocyte Disorders with other initiatives, grown within the EHA environment, related to Constitutional Marrow Failure…

Read more

Introducing YoungEHA: you don’t have to grow old to make a difference

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee. Hearing exciting new research, attending lectures by leaders in the field, and networking are some of the obvious things that are happening during the annual EHA congress.

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more